Sciatalgia. Lumbar and other intervertebral disc disorders with radiculopathy (G55.1*) Sciatica due to intervertebral disc disorder
Conditions
Interventions
Intervention 1: Intervention group 1: patients in this group received 80 mg Mehtylprednisolone (Manufactured by Caspian Tamin Darou Iran) plus 15ml 0.5%w/v Bupivacaine (75mg) Manufactured by Merck in
Treatment - Drugs
Intervention group 1: patients in this group received 80 mg Mehtylprednisolone (Manufactured by Caspian Tamin Darou Iran) plus 15ml 0.5%w/v Bupivacaine (75mg) Manufactured by Merck industries in Fran
Intervention group 2: patients in this group received 80mg Methylprednisolone plus 8ml 0.5%w/v Bupivacaine (40mg) from sacral hiatus into Caudal space under fluoroscopy and contrast guidance by 18 Gag
Sponsors
Vice Chancellor for Research, Faculty of Medicine,Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with disc herniation in one level; aged 30-70. Exclusion criteria: canal stenosis; opiate abuse; psychotic disorders history of allergic reactions to drugs; anatomical disorders in vertebral column
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: every month until 6th month. Method of measurement: visual analog scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rang of Motion. Timepoint: every month until 6th month. Method of measurement: leg rise test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDawood Aghamohammadi
Anesthesiology Dept, Faculty of Medicine, Tabriz University of Medical Science
Outcome results
None listed